Histofy, a spin-out company from The University of Warwick, has developed an innovative artificial intelligence (AI) tool to enhance cancer diagnosis and treatment. This device, designed by scientists, assists medical professionals in grading cancer by analyzing cell division within tumors.
Counting dividing cells is crucial in determining the aggressiveness or grade of the cancer, which in turn influences treatment decisions. Traditional methods of counting cell division have been deemed time-consuming and unreliable by the scientists at Histofy.
To overcome these challenges, Histofy has introduced MitPro. This AI-powered tool efficiently counts and profiles the division of cancer cells across entire tumor samples, pinpointing the most relevant areas for detailed analysis. The primary goal of MitPro is to improve the standard of care in grading various types of cancers, including breast cancer and sarcomas.
Simon Graham, the Chief Technology Officer of Histofy at the University of Warwick’s computer science department, highlighted the significant potential of AI in cancer care. According to Graham, “MitPro enhances current grading systems for a range of cancers by providing a more accurate assessment of the rate at which cancer cells are dividing.” This technological advancement represents a significant step forward in cancer diagnosis and treatment.
For more tech news and insights, visit Rwanda Tech News, and explore similar topics and trends in the world of technology.
